Implementation Science to Improve Tobacco Cessation Services in Oncology Care
Search for other papers by The Cancer Center Cessation Initiative Implementation Science Working Group in
Current site
Google Scholar
PubMed
Every patient with cancer deserves access to evidence-based tobacco cessation interventions as part of their routine oncology care. The NCI Cancer Moonshot funded the Cancer Center Cessation Initiative (C3I) to help establish and/or expand tobacco treatment programs at 52 NCI-designated Cancer Centers. Although this initiative has broadened the availability of tobacco treatment services across US cancer centers, the reach and utilization of these services remains low among patients. To help address the remaining gap between the availability and utilization of evidence-based treatments for tobacco use in the oncologic context, staff and investigators at C3I sites and the C3I Coordinating Center formed the C3I Implementation Science Working Group. The mission of this working group is to bring together clinicians, scientists, and policymakers who share a common interest in implementation science and treating tobacco use in the oncologic context to collaborate on projects aimed at shrinking the practice gap in this area. Through case study examples, we describe how the C3I Implementation Science Working Group is supporting efforts to identify effective ways to increase the utilization of evidence-based tobacco treatments within cancer treatment settings and promote the broader impact and long-term sustainability of C3I.
The Cancer Center Cessation Initiative Implementation Science Working Group
Robert Schnoll PhD1, Li-Shiun Chen MD, MPH, ScD2, Alex T. Ramsey PhD2, Cary A. Presant MD, FACP, FASCO3, Thulasee Jose MD4, Kimlin T. Ashing PhD5, Donna Shelley MD, MPH6, Steven L. Bernstein MD7, Linda Fleisher PhD, MPH8, Ramzi G. Salloum PhD9, Graham W. Warren MD, PhD10, Kara P. Wiseman PhD, MPH11, Janice A. Blalock PhD12, Neely A. Dahl MPH13, Edlira B. Farka APRN14, Donna Manders MPH, CTTS15, Jamie S. Ostroff PhD16, Elyse R. Park PhD, MPH17, Robert Adsit MEd18, Sarah D. Hohl MPH, PhD19, Mara Minion MA19, Danielle Pauk BS19, and Betsy Rolland PhD, MLIS, MPH19,20
1 Department of Psychiatry and Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania; | 2 Department of Psychiatry and Siteman Cancer Center, Washington University in St. Louis, St. Louis, Missouri; | 3 Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, and Beckman Research Institute, Duarte, California; | 4 Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, Minnesota; | 5 Department of Population Sciences, City of Hope National Medical Center, Duarte, California; | 6 Department of Policy and Public Health Management, School of Global Public Health, New York University, New York, New York; | 7 Department of Emergency Medicine, Geisel School of Medicine, Dartmouth College, Hanover, New Hampshire; | 8 Fox Chase Cancer Center, Philadelphia, Pennsylvania; | 9 Department of Health Outcomes & Biomedical Informatics, College of Medicine, University of Florida, Gainesville, Florida; | 10 Department of Radiation Oncology, Department of Cell and Molecular Pharmacology, Medical University of South Carolina, Charleston, South Carolina; | 11 Department of Public Health Sciences, School of Medicine, University of Virginia, Charlottesville, Virginia; | 12 Department of Behavioral Science, University of Texas MD Anderson Cancer Center, Houston, Texas; | 13 University of Virginia Cancer Center, Charlottesville, Virginia; | 14 Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah; | 15 Seattle Cancer Care Alliance, Seattle, Washington; | 16 Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, New York; | 17 Department of Psychiatry, Massachusetts General Hospital (MGH), Boston, Massachusetts; | 18 Department of Medicine, Center for Tobacco Research and Intervention, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin; | 19 Carbone Cancer Center, University of Wisconsin-Madison, Madison, Wisconsin; and | 20 Institute for Clinical and Translational Research, University of Wisconsin-Madison, Madison, Wisconsin.
Submitted July 26, 2021; final revision received September 14, 2021; accepted for publication September 16, 2021.
Disclosures: G.W. Warren has disclosed participating in research for the Agency for Healthcare Research and Quality and serving as a consultant for the Canadian Partnership Against Cancer. The remaining individuals have disclosed no relevant financial relationships.
Funding: This supplement was funded by the C3I Coordinating Center contract from the National Cancer Institute (CRDF Award #66590). In addition, authors received funding for their C3I participation via a supplement to their NCI P30 cancer center support grant during the period 2017–2021.
© 2019-2024 National Comprehensive Cancer Network